Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02435433 |
| Title | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2) |
| Acronym | REACH-2 |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Eli Lilly and Company |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS |